<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> increases <z:hpo ids='HP_0003002'>breast cancer</z:hpo> risk and mortality, and <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> has been identified as a major factor linking these two diseases </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, we hypothesized that pharmacological reduction of elevated insulin levels would attenuate type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-mediated <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> progression </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We studied <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> development in MKR(+/+) mice, a nonobese, hyperinsulinemic mouse model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>MKR(+/+) mice were either crossed with mice expressing the polyoma virus middle T oncogene specifically in the mammary gland or inoculated orthotopically with the mouse <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> cell lines Met-1 and MCNeuA </plain></SENT>
<SENT sid="4" pm="."><plain>MKR(+/+) or control mice harboring <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were treated with CL-316243, a specific beta3-<z:chebi fb="0" ids="37886">adrenergic receptor agonist</z:chebi>, which sensitizes insulin action but has no direct effect on the mouse mammary epithelium or Met-1 and MCNeuA cells </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: CL-316243 treatment significantly reduced the elevated insulin levels in MKR(+/+) mice and, as a consequence, attenuated <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> progression in the three <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models tested </plain></SENT>
<SENT sid="6" pm="."><plain>This effect was accompanied by reductions in phosphorylation of insulin and IGF-I receptors in transformed mammary tissue </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Insulin-sensitizing treatment is sufficient to abrogate type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-mediated <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">mammary tumor</z:e> progression </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, early administration of insulin-sensitizing therapy may reduce <z:hpo ids='HP_0003002'>breast cancer</z:hpo> risk and mortality in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>